Abstract
Body weight loss, caused by surgical stress, morbidity, post-gastrectomy syndrome, and so on, is a common finding after gastric cancer surgery. Body and fat weight are continuously decreasing after surgery, while muscle weight increases from 3 months after surgery. Body weight loss more than 15％ to the preoperative weight was reportedly a risk factor for continuation of S-1 adjuvant chemotherapy but its clinical significance has been reduced because severe weight loss could be prevented by recent sophisticated perioperave care such as ERAS protocol. On the other hand, newly identified lean body mass loss of more than 5％ to the preoperative mass is a sensitive indicator for continuation of S-1 adjuvant chemotherapy. Effects of preoperative training or laparoscopic surgery on prevention of muscle loss are controversial. EPA-enriched enteral nutrition, ghrelin administration, and enhanced calorie administration are now investigated in clinical trial.
